After the Japanese mega pharma company bought TiGenix for 630 million dollars back in January, they are ready to acquire Shire for a whopping 64 billion dollars. This will make Takeda the 8th-largest pharmaceutical company in the world (currently in 19th place)
Not everyone is excited
Not all the shareholders of Takeda and those of Shire are excited about the deal though, as Takeda’s stock plummeted by 7% on Wednesday morning. They are worried that Takeda is biting off more than they can chew in this deal, as Shire is about twice the size of their current market value.
Because Takeda’s stock is going down, it’s becoming less interesting for Shire-shareholders.
Takeda is known on the Japanese stock market as a safe investment, while Shire is not.
The Belgium biotech TiGenix is positive about the deal. For Shire, the deal would mean another twist in a story of massive growth for the rare-diseases specialist in the past years.
Another bidder for Shire is unlikely to emerge at this point. Although not all agree if the deal will go through or not.
The deadline for the deal is set on the 8th of May.
Last modified: April 26, 2018